Why Moderna, Inc. (MRNA) Stock Rose 177.0% on Aug 19, 2026
The clearest new catalyst: Phase 3 INTerpath-001 topline win (announced Aug 19, pre-market).
Why did MRNA stock rise?
Moderna shares nearly tripled on Wednesday, August 19, 2026 after Moderna and Merck announced that their individualized mRNA cancer therapy — intismeran autogene (formerly mRNA-4157/V940), used in combination with Merck's Keytruda — met the primary recurrence-free-survival endpoint and a key distant-metastasis-free-survival endpoint in the Phase 3 INTerpath-001 melanoma trial. The pre-market announcement drove a +176.97% close-to-close move, the biotech's best day ever.
- Phase 3 INTerpath-001 topline win (announced Aug 19, pre-market): Before the open (around 7 a.m. ET), Moderna and Merck reported that intismeran autogene plus Keytruda (pembrolizumab) met the primary endpoint — recurrence-free survival — and a key secondary endpoint — distant-metastasis-free survival — in resected high-risk melanoma, a first-of-its-kind late-stage win for an individualized neoantigen (mRNA cancer-vaccine) therapy.
- The '49% reduction' figure is from an EARLIER study, not this Phase 3: The widely cited ~49% reduction in recurrence or death (and ~59% reduction in distant metastasis or death) comes from the earlier Phase 2b KEYNOTE-942 five-year follow-up. The new Phase 3 topline only disclosed statistically significant, clinically meaningful improvements on those endpoints; the Phase 3 hazard ratios and effect sizes were not yet released.
- A Moderna-and-Merck program: Intismeran autogene is developed jointly by Moderna and Merck and is designed to be given with Merck's Keytruda — so the readout is a shared catalyst (Merck shares also rose on the news).
How the story developed
- Earlier (Phase 2b KEYNOTE-942)The five-year follow-up of the Phase 2b study showed a ~49% reduction in recurrence or death and ~59% reduction in distant metastasis or death — the basis for the program's promise.
- August 19, 2026 (pre-market, ~7 a.m. ET)Moderna and Merck announce positive Phase 3 INTerpath-001 topline: intismeran autogene plus Keytruda met the RFS (primary) and DMFS (key secondary) endpoints in melanoma.
- August 19, 2026 (close)MRNA closes up 176.97% at $174.38 on roughly 28x average volume — its best day ever.
What it could mean for MRNA investors
The constructive case
- A Phase 3 win validates the individualized-neoantigen (mRNA cancer-vaccine) approach and Moderna's oncology pipeline beyond COVID vaccines — a potential new growth pillar.
- The therapy is partnered with Merck and paired with Keytruda, aligning it with a blockbuster franchise and a well-capitalized partner.
The cautious case & what could invalidate it
- The Phase 3 topline disclosed only that endpoints were met — the actual hazard ratios, magnitude of benefit and safety detail have not yet been released, so the market is pricing an incomplete readout.
- A near-tripling in a single session prices in a great deal; commercialization, regulatory review and broader indications are still ahead.
- The stock had been deeply depressed (prior close under $63), so part of the move is a re-rating from a low base rather than a change in current revenue.
Initial detection
BestStocks first flagged MRNA intraday on Aug 19, 2026; this analysis was finalized after the close using the confirmed +177.0% session move and additional catalyst research.
Show the initial intraday note
Moderna, Inc. (MRNA) nearly tripled — up 176.97% from a prior close of $62.96 to $174.38 on Wednesday, August 19, 2026 — after Moderna and Merck announced positive topline Phase 3 results for their individualized mRNA cancer therapy, intismeran autogene, in melanoma. The announcement came pre-market (around 7 a.m. ET) and the stock surged on roughly 28x average volume.
What to watch next: The companies have not yet disclosed the Phase 3 INTerpath-001 hazard ratios/effect sizes or the full data — the next catalyst is that detailed readout (and any regulatory-filing plans). Watch how the therapy's melanoma results read across Moderna and Merck's other cancer-vaccine indications.
Frequently asked questions
Why did Moderna, Inc. (MRNA) stock rise on Aug 19, 2026?
Moderna shares nearly tripled on Wednesday, August 19, 2026 after Moderna and Merck announced that their individualized mRNA cancer therapy — intismeran autogene (formerly mRNA-4157/V940), used in combination with Merck's Keytruda — met the primary recurrence-free-survival endpoint and a key distant-metastasis-free-survival endpoint in the Phase 3 INTerpath-001 melanoma trial. The pre-market announcement drove a +176.97% close-to-close move, the biotech's best day ever.
How much did MRNA stock rise on Aug 19, 2026?
MRNA rose 177.0% during the Aug 19, 2026 trading session.
What were the main drivers behind MRNA's move?
Phase 3 INTerpath-001 topline win (announced Aug 19, pre-market); The '49% reduction' figure is from an EARLIER study, not this Phase 3; A Moderna-and-Merck program.